Mayo Clinic Laboratories’ IBDP2 serology panel detects for the presence of antibodies against Saccharomyces cerevisiae IgA and IgG, and anti-neutrophil cytoplasmic antibodies (pANCA) to confirm disease presence in patients for whom diagnosis is unclear. In this test specific episode of the  "Answers From the Lab" podcast, Melissa Snyder, Ph.D., explains how IBDP2, when used after first-line testing has failed, can distinguish between ulcerative colitis and Crohn’s disease.

“Ulcerative colitis and Crohn's disease are really clinical diagnoses where the physician takes into account the clinical picture, some imaging studies, and maybe pathology to make a diagnosis,” Dr. Snyder says. “And for most patients, this is enough. Inflammatory bowel disease serology testing can be useful in a small subset of patients to help when it's difficult to differentiate between ulcerative colitis and Crohn's disease.”

Inflammatory bowel disease serology testing at Mayo Clinic Laboratories incorporates measures that improve testing quality and ensure accuracy of test results, Dr. Snyder adds. “We want to make sure that when we provide a result to a patient, the patient can rely on that result, the physician can rely on that result.”

Listen to learn more about how IBDP2 can help distinguish between ulcerative colitis and Crohn’s disease for some patients with IBD.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

IBDP2  | Inflammatory Bowel Disease Serology Panel, Serum

Useful information

• Distinguishing between ulcerative colitis and Crohn disease in patients for whom the specific diagnosis is unclear based on endoscopic, pathologic, and imaging evaluations.
• This test is not useful for determining the extent of disease in patients with inflammatory bowel disease or determining the response to disease-specific therapy including surgical resection of diseased intestine.

Specimen requirements

Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Specimen Volume: 1 mL

Performance information

• Analytic time: Same day/1 day
• Day(s) and time(s) performed: TBD

The latest

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

September 24, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

September 17, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

September 10, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

View MoreView Less